The U. S. Food and Drug Administration (FDA) said on September 16 that AstraZeneca’s COVID-19 vaccine trial in the United States was still pending and that officials were investigating with the company whether there was a significant protection factor or not. -19 vaccine trial last week after a patient who volunteered for the vaccine trial became ill.
While the UK-based company is still investigating whether a candidate’s sudden illness is a serious-looking effect of the vaccine, Commissioner Stephen Hahn said the FDA was still looking for her. The officials did not yet have all the facts and did not know the cause consistent with the se. However, he added that “primary responsibility” is the safety of the American people.
READ: Trump says COVID-19 vaccine may be available ‘within a month’ at Pennsylvania convention
The US essay is a us-in-the-world test. But it’s not the first time It remains unresolved as the FDA and the protection committee are still investigating the case. AstraZeneca, who is preparing a COVID-19 vaccine in partnership with Oxford University, announced that he had suspended his vaccine trial on 6 September.
READ: COVID-19 Vaccine: Serum Institute Gets DCGI Approval to Resume Two, 3 Trials
The AstraZeneca vaccine, called AZD1222, has been described in the past by WHO as a pioneer and one of the most complex clinical trials. Last week, the company announced that its popular review procedure had caused a pause in vaccination to allow for a review of protection. However, the company did not provide more data on imaginable side effects rather than simply calling them “a potentially unexplained disease. “
Temporary suspensions of primary vaccine test studies are very common. In addition, it is mandatory for the company to investigate all serious and unforeseen reactions of the candidate to perform certain verification checks. possibly a coincidence, as diseases of all kinds can occur in such vaccine test studies.
READ: Coronavirus: ”Three vaccines at the test level in India’, says ICMR
READ: Poland seeks more flu vaccines due to scarcity pandemic